TiumBio 관리

관리 기준 확인 0/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Huntaek Kim

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	31.5%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	데이터 없음

최근 관리 업데이트

업데이트 없음

Recent updates

We Think TiumBio (KOSDAQ:321550) Has A Fair Chunk Of Debt

Jun 20

CEO

Huntaek Kim (58 yo)

no data

테뉴어

Mr. Hun-Taek Kim serves as Chief Executive Officer of TiumBio Co. Ltd. He received his Bachelor's degree from College of Veterinary Medicine, Seoul National University, Master's degree from College of Vete...

TiumBio 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

Recent updates

New minor risk - Share price stability

New minor risk - Market cap size

TiumBio Co., Ltd. Announces First Patient Dosed in Phase 2 Clinical Trial of Oral Immuno-Oncology Drug TU2218

TiumBio Co., Ltd. Presents Promising Clinical Data from Phase 1 of its Hemophilia Treatment Candidate TU7710 at ISTH 2024

We Think TiumBio (KOSDAQ:321550) Has A Fair Chunk Of Debt

Tiumbio Co., Ltd. Presents Phase 1B Interim Results for Tu2218 in Combination with Pembrolizumab At Asco 2024 Annual Meeting

TiumBio Co., Ltd. Announces Positive Topline Data from Phase 2A Trial of Merigolix in Patients with Moderate to Severe Endometriosis-Associated Pain

Tiumbio Co., Ltd. Submits CTA for Phase 1B Clinical Trial of TU7710, A Long-Acting Recombinant Activated Factor VII, in Hemophilia A or B Patients

TiumBio Co., Ltd. Announces to Initiate Phase 2 Trial of TU2218 for Cancer

New minor risk - Revenue size

New minor risk - Shareholder dilution

TiumBio Co., Ltd. announced that it has received KRW 49.99982815 billion in funding

TiumBio Co., Ltd. announced that it has received KRW 25 billion in funding

New 90-day low: ₩16,000

New 90-day high: ₩18,000

New 90-day high: ₩18,900

New 90-day high - ₩17,950

CEO

테뉴어